An in vitro vascularized micro-tumor model of human colorectal cancer recapitulates in vivo responses to standard-of-care therapy

Around 95% of anti-cancer drugs that show promise during preclinical study fail to gain FDA-approval for clinical use. This failure of the preclinical pipeline highlights the need for improved, physiologically-relevant in vitro models that can better serve as reliable drug-screening and disease mode...

Descripción completa

Detalles Bibliográficos
Autores principales: Hachey, Stephanie J., Movsesyan, Silva, Nguyen, Quy H., Burton-Sojo, Giselle, Tankazyan, Ani, Wu, Jie, Hoang, Tuyen, Zhao, Da, Wang, Shuxiong, Hatch, Michaela M., Celaya, Elizabeth, Gomez, Samantha, Chen, George T., Davis, Ryan T., Nee, Kevin, Pervolarakis, Nicholas, Lawson, Devon A., Kessenbrock, Kai, Lee, Abraham P., Lowengrub, John, Waterman, Marian L., Hughes, Christopher C. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2021
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525497/
https://www.ncbi.nlm.nih.gov/pubmed/33605955
http://dx.doi.org/10.1039/d0lc01216e

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525497/
https://www.ncbi.nlm.nih.gov/pubmed/33605955
http://dx.doi.org/10.1039/d0lc01216e

Ejemplares similares